What does the GKV-BStabG Reform Change for Pharma Pricing & Reimbursement in Germany? And the Reforms Are Not Over: What to Expect From the New German Minister of Health and the Pharma Dialogue? (JSON)

lexblog.com/lib/78D009THview recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "What does the GKV-BStabG Reform Change for Pharma Pricing & Reimbursement in Germany? And the Reforms Are Not Over: What to Expect From the New German Minister of Health and the Pharma Dialogue?",
    "url": "https://www.lexblog.com/2026/08/03/what-does-the-gkv-bstabg-reform-change-for-pharma-pricing-reimbursement-in-germany-and-the-reforms-are-not-over-what-to-expect-from-the-new-german-minister-of-health-and-the-pharma-dialogue/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-78D009TH",
        "url": "https://www.lexblog.com/lib/78D009TH/"
    },
    "datePublished": "2026-08-03T23:24:13-04:00",
    "dateModified": "2026-08-03T23:24:22-04:00",
    "author": {
        "@type": "Person",
        "name": "Dr. Dr. Adem Koyuncu, Maximilian Aretz"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Covington & Burling LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Global Policy Watch",
    "about": "Business and Commercial · Health Care and Life Sciences",
    "sourceUrl": "https://www.globalpolicywatch.com/?p=16714",
    "sourceStability": "may-move"
}